



Biotech Daily

Thursday September 4, 2025

Daily news on ASX-listed biotechnology companies

- * **ASX, BIOTECH UP: STARPHARMA UP 16%; CURVEBEAM DOWN 21%**
- * **FDA CLEARS COMPUMEDICS SOMFIT D SLEEP TEST**
- * **BRANDON CUREATOR \$1.2m MRFF, CSIRO 'TOP-UP' GRANTS**
- * **AMPLIA DOSES 1st AMP945, FOLFIRINOX PANCREATIC CANCER PATIENT**
- * **MESOBLAST: \$76.5m CONVERTIBLE NOTE WITH SURGCENTER**
- * **ACRUX RECEIVES \$3m FEDERAL R&D TAX INCENTIVE**
- * **ALTERITY REQUESTS 'CAPITAL RAISING' TRADING HALT**
- * **ANTERIS DELAYS MEETING TO 'FACILITATE BROADER PARTICIPATION'**
- * **CITIGROUP TAKES 5.2% OF CLARITY**
- * **SACAVIC, MORRIS SUPER INCREASE, DILUTED TO 13% OF ADALTA**
- * **NEIL DELROY TAKES 6% OF ARGENICA**

MARKET REPORT

The Australian stock market rebounded 1.0 percent on Thursday September 4, 2025, with the ASX200 up 87.7 points to 8,826.5 points.

Nineteen of the Biotech Daily Top 40 companies were up, 11 fell, nine traded unchanged and one was untraded.

Starpharma was the best, up 1.75 cents or 15.6 percent to 13 cents, with 387,301 shares traded. 4D Medical improved 13.4 percent; Compumedics climbed 12.5 percent; Actinogen, Cynata, Impedimed and Neuren were up five percent or more; Micro-X was up four percent; Dimerix and Paradigm climbed more than three percent; CSL, Immutep, Medadvisor, Mesoblast and SDI rose more than two percent; Clarity, Clinuvel, Nova Eye, Polynovo and Pro Medicus were up one percent or more; with Cochlear and Orthocell up by less than one percent.

Curvebeam led the falls, down three cents or 21.4 percent to 11 cents, with 864,212 shares traded. Optiscan lost 8.2 percent; Cyclopharm fell 4.4 percent; Emvision and Telix shed more than two percent; Avita, Imricor, Imugene, Nanosonics and Syntara were down more than one percent; with EBR and Resmed down by less than one percent.

COMPUMEDICS

Compumedics says the US Food and Drug Administration has granted 510(k) clearance for its single-use Somfit D sleep test device.

Compumedics said the clearance expanded its access to an estimated \$US240 million (\$A367 million) yearly US home sleep testing market, and it was targeting 10 percent to 30 percent market penetration by July 2027.

The company said it had a US salesforce “in place” and had engaged providers, with commercial rollout to begin immediately.

Compumedics said that the electro-encephalo-graph (EEG)-based, single-use Somfit D “complements the reusable Somfit, creating the only EEG-based platform serving both high-volume single-use and multi-night reusable diagnostic markets”.

Compumedics chief executive officer Dr David Burton said “the FDA clearance of Somfit D is a transformational milestone for Compumedics”.

“With a single-use device engineered for scale, we are entering the US sleep diagnostics market with a disruptive solution that directly addresses provider needs,” Dr Burton said.

“Together with the reusable Somfit, we are positioned to capture meaningful share of a market worth up to \$US240 million annually and to accelerate our recurring revenue growth for years to come,” Dr Burton said.

The company said Somfit D was cleared for sale in Australia, New Zealand, the European Union and the US, and re-affirmed its guidance of revenue for the year to June 30, 2026 of “at least \$70 million revenue and \$9 million earnings before interest, taxes, depreciation and amortization (Ebitda)”.

Compumedics rose 3.5 cents or 12.5 percent to 31.5 cents with 1.5 million shares traded.

BRANDON CAPITAL

Brandon Capital says its Cureator will provide \$1.23 million in “top-up” funding to six companies in its pre-clinical and anti-microbial resistance research streams.

Brandon Capital managing partner Dr Chris Nave told Biotech Daily that the Federal Government’s Medical Research Future Fund (MRFF) and Commonwealth Scientific and Industrial Research Organisation (CSIRO) grants were “allocated to companies that met previously determined milestones”.

Brandon said that \$668,710 would be awarded to the pre-clinical research stream, through the MRFF “early-stage translation and commercialization support” grant, in addition to the \$2.5 million awarded to these companies in previous funding rounds.

The company said the pre-clinical stream included Frontier Inflammasome Therapeutics’ research on small molecule inhibitors for inflammatory lung and skin conditions; Rage Biotech’s inhaled RNA therapy for chronic lung disease; Cincera Therapeutics’ treatments for fibrotic disease; and Xcystence Bio’s treatments for polycystic kidney disease.

Brandon said that \$570,000 would be awarded to its “Minimizing Anti-microbial Resistance” research stream, provided by the CSIRO, in addition to the \$930,000 awarded to these companies in the first funding round.

The company said that the anti-microbial resistance stream included Clinical Branches’ software-as-service platform that helped clinicians better prescribe anti-microbial treatments by integrating patient data with clinical pathways; and Spritz-OM’s research program developing a nasal probiotic therapy to prevent childhood ear infections and reduce the overuse of antibiotics.

“By providing timely, targeted follow up funding, Cureator helps bridge the gap between early-stage innovation and investor-ready progress, ensuring promising biotechs can maintain momentum,” Dr Nave said.

AMPLIA THERAPEUTICS

Amplia says it has dosed the first of 67 patients in its phase Ib/IIa trial of AMP945, or narmafotinib, in combination with Folfirinox for pancreatic cancer.

Previously, Amplia said it had Australian and US approval for the phase Ib/IIa trial of focal adhesion kinase (FAK) inhibitor narmafotinib with Folfirinox (5-fluorouracil, leucovorin, irinotecan and oxaliplatin) for metastatic pancreatic cancer and had opened trial sites in Sydney and Melbourne (BD: Jul 30, Aug 29, 2025).

Today, the company said the trial's first stage would explore safety, tolerability and pharmaco-kinetics of increasing daily doses of narmafotinib combined with Folfirinox given on its conventional two-week cycle, with dosing expected to be completed by April 2026. Amplia chief executive officer Dr Chris Burns said that dosing the first patient was "an important milestone in the development of narmafotinib".

Amplia was unchanged at 16 cents with 6.1 million shares traded.

MESOBLAST

Mesoblast says it has an up-to \$US50 million (\$A76.6 million) convertible note subscription option with Surgcenter's Gregory George and William Gueck.

Mesoblast said Mr George and Mr Gueck were principals in the Baltimore, Maryland-based Surgcenter and Mesoblast investors, and would receive a commitment fee of \$US100,000 and two million warrants over two million shares, or 200,000 Mesoblast American depositary receipts (ADRs), for entering in the convertible note option, and a further three million warrants should Mesoblast exercise the option.

The company said funds would repay or reduce the amount owed to lenders.

Mesoblast said pending investor approval, it could issue up to \$US50 million in \$US10 million tranches of notes, within five years, unless redeemed or converted earlier.

Mesoblast said Mr George and Mr Gueck could elect to convert the notes into shares or ADRs at the conversion price of \$US16.25 per ADR, at any time up to the maturity date.

The company said the ADR conversion price was 126 percent of its last closing price on the Nasdaq and a 29 percent premium to the last closing price on the ASX, and the notes had a coupon of five percent a year on the value of the issued notes.

Mesoblast said the warrants would have the same exercise price as the conversion price of the notes, with a maturity date of four years from the date of issuance.

Mesoblast was up five cents or 2.6 percent to \$1.99 with 7.5 million shares traded.

ACRUX

Acrux says it has received \$3,040,367 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.

Acrux said the incentive related to expenditure for the year to June 30, 2025, and had fully repaid its related loan from Melbourne's Radium Capital.

In April, the company said it had a \$1.73 million loan from Radium (BD: Apr 3, 2025).

Acrux was up 0.1 cents or 7.7 percent to 1.4 cents with 2.1 million shares traded.

ALTERITY THERAPEUTICS

Alterity has requested a trading halt pending an announcement "in relation to a capital raising".

Trading will resume on September 8, 2025 or on an earlier announcement.

Alterity last traded at 1.3 cents.

ANTERIS TECHNOLOGIES GLOBAL CORP

Anteris says it has postponed its special meeting to provide shareholders “additional time to vote in order to facilitate broader participation”.

Anteris said the online meeting, initially scheduled for 5pm US Central Time on September 4, 2025 or September 5, 2025 at 8am (AEST), would be held on September 11, 2025 at 5pm US Central Time, or September 12, 2025 at 8am (AEST).

Last month, Anteris said it had a “waiver from ASX Listing Rule 7.1 to issue new securities without obtaining security holder approval” (BD: Aug 8, 2025).

The company said ASX Listing Rule 7.1 restricted “listed entities from issuing securities in excess of 15 percent of their issued share capital without security holder approval over a 12-month period unless an exception applies”.

Anteris fell seven cents or 1.15 percent to \$6.00.

CLARITY PHARMACEUTICALS

Citigroup Global Markets Australia Pty Ltd says it has become a substantial shareholder in Clarity 19,474,367 shares or 5.236 percent of the company.

The Sydney and London-based Citigroup said it acquired the shares through a securities lending agency agreement, but did not disclose prices.

Clarity was up three cents or 1.0 percent to \$3.13 with 2.1 million shares traded.

ADALTA

Sacavic Pty Ltd and the Morris Super Fund say they have increased but been diluted in Adalta from 97,441,722 shares (16.36%) to 166,108,388 shares (12.57%).

Melbourne’s Stuart Morris said shares were bought and sold between August 20, 2024 and June 25, 2025, with the single largest purchase in a rights offer on June 4, 2025 of 66,666,666 shares for \$200,000 or 0.3 cents a share.

In June, Adalta said it raised \$1,090,452 of a hoped for \$1,300,000 at 0.3 cents a share, and later said it had placed \$193,830 of the \$209,548 shortfall (BD: Jun 3, 13, 2025).

Adalta was unchanged at 0.3 cents with 1.6 million shares traded.

ARGENICA

The Busselton, Western Australia-based Neil Delroy says he has increased his shareholding in Argenica from 5,020,916 shares (5.11%) to 8,240,633 shares (6.42%).

Mr Delroy said that between June 26, 2023 and September 3, 2025 he bought shares on market and through a placement, with the single largest purchase on April 16, 2024 of 1,600,000 shares for \$832,000 or 52 cents a share.

Last year, Argenica said it had “commitments” for a \$12.0 million placement at 52.0 cents a share (BD: Apr 12, 2024).

Argenica fell three cents or 10.7 percent to 25 cents with 4.9 million shares traded.